CARsgen Therapeutics has announced a collaboration agreement with Moderna to jointly investigate the potential of combining CARsgen's investigational Claudin18.2 CAR T-cell product candidate, known as CT041, with Moderna's investigational Claudin18.2 mRNA cancer vaccine.
The aim of this collaboration is to conduct preclinical studies and a phase I clinical trial that will assess the effectiveness of the combination therapy.
The focus of this partnership is to explore the synergistic effects of combining CAR-T cell therapy with an mRNA cancer vaccine designed to encode the Claudin18.2 protein. Claudin18.2 is a promising target for therapeutic intervention, especially in cases of various cancer types where there is a significant unmet medical need.
CT041, also referred to as satricabtagene autoleucel, is CARsgen's proprietary CAR T-cell product that is derived from the patient's own cells. It is being investigated as a potential treatment for gastrointestinal cancers, including gastric and pancreatic cancers.
The therapy has shown promising results in ongoing clinical studies conducted in both China and North America, further bolstering its potential to effectively address these challenging cancer types.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!